Plaque Psoriasis

The study’s findings bring major lessons for dermatologists to light, the most apparent of which being that many reasons for discordance between clinicians and patients may be modified.

This segment of her interview with HCPLive featured a discussion with Ferris on the FRONTIER 1 phase 2b trial results and their implications for psoriasis patients.

New phase 2b data from the FRONTIER 1 study showed promise for what could become the first and only oral IL-23 antagonist peptide for psoriasis.

While the unmet needs of patients of color is a growing concern in the dermatology world, more has to be done to address the obvious disparities in care.

This new data indicated the strong safety profile and efficacy of CAL/BDP-cream using PAD technology for psoriasis patients, and could lead to better adherence and outcomes in real-world settings.

This systematic review and meta-analysis demonstrated the potential effectiveness of JAK inhibitors for alopecia, though further trials are needed for long-term use.

Mona Shahriari, MD, reviews the efficacy data of topical treatments in the treatment of plaque psoriasis, and Linda Stein Gold, MD, discusses unmet needs in the plaque psoriasis treatment landscape.

Experts share the difference between the remittive and the suppressive effect in plaque psoriasis and how to get patients there.

In these preliminary results from the ongoing POSITIVE study, tildrakizumab was shown to have led to significant improvement for psoriasis patients.

Both biologic-naïve and biologic-experience patients saw benefits in the BRIGHT study examining therapeutic response to brodalumab over the course of 1 year.

New clinical trial data shows benefits of spesolimab for GPP flares, providing compelling evidence for IL-36 signaling’s effect on the condition’s pathogenesis.

Expert dermatologists discuss plaque psoriasis in difficult-to-treat areas such as skin folds and the face, highlighting which types of treatments they recommend.

Linda Stein Gold, MD; Mona Shahriari, MD; and Michael Cameron, MD, FAAD, share approaches to choosing between systemic and topical therapies or combination therapies to treat plaque psoriasis.

Experts discuss the current standard of care for patients with moderate-to-severe plaque psoriasis, focusing on whether the patient is a candidate for systemic or topical treatment.

Expert dermatologists provide an overview of the current topical, oral, and biologic medications available to treat plaque psoriasis.

Describing the biggest takeaways from her talk ‘Diagnosis and Management of Blistering Disorders,’ Dr. Noe went in depth about treatment of blistering in patients.

This interview with Dr. Noe at the SDPA conference featured a discussion about her background and her presentation titled ‘Diagnosis and Management of Blistering Disorders.'

In another interview segment, Dr. Amin described some of the other biggest points from his conference talk on choosing the best route for psoriasis in patients.

In this interview segment, Dr. Amin described some of the major takeaways from his conference talk titled ‘Biological Bootcamp: How to Select the Best Biologics for Your Psoriasis Patient.’

In a conference presentation, Dr. Imadojemu discussed the topic of afro-textured hair and various hair and scalp disorders.

In research presented at the 2023 SDPA summer conference, new pharmacovigilance data over a 4-year span aligned with the established safety profile on brodalumab.

In this interview segment, Dr. Barbieri explained the major takeaways from his conference talk on acne and rosacea with a focus on the more severe levels of these conditions.

In this conference interview, Dr. Barbieri described some of the major takeaways from his talk on foundational tools for patients with acne and rosacea.

During this conference talk, Dr. Nicole Gunasekera spoke about options for acne scar treatments such as chemical peels and microneedling, as well as special considerations for richly-pigmented skin.

In his conference presentation, Dr. Arash Mostaghimi reviewed the ways to ensure access to the right information from a biopsy as well as how to interpret potentially confusing biopsy results.

These new findings suggest the need for expansion of JAK1/JAK2 targeting approaches for treatment of eosinophilic cellulitis and other types of eosinophilic disease.

This new data emphasizes the vital importance of timely detection and effective treatment for squamous cell carcinomas in this particular population.

This new tool, using an automated analysis of different parts of the body, could help clinicians to address previously unmet needs for treatment in conditions such as psoriasis.

These new guidelines were developed to benefit younger patients with inflammatory skin diseases, and may be helpful given the inexpensive nature and general availability of the drug.

In this episode of MEDcast, expert dermatologists discuss exciting advancements in systemic therapies such as JAK inhibitors, and the latest breakthroughs in topical treatments for plaque psoriasis